nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.06.2004 | Original Article

The clinical relevance of thymic fluorodeoxyglucose uptake in pediatric patients after chemotherapy

verfasst von: Tsuyoshi Kawano, Akiko Suzuki, Amane Ishida, Nobukazu Takahashi, Jin Lee, Yoshifumi Tayama, Takashi Oka, Shumpei Yokota, Tomio Inoue

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 6/2004

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this study was to clarify the clinical implications of thymic fluorodeoxyglucose (FDG) uptake after chemotherapy in pediatric patients with malignant disease. Twenty-two pediatric patients, aged 0–17 years (mean 7.0 years), who had undergone FDG positron emission tomography (PET) were examined retrospectively. A total of 48 FDG-PET scans of the 22 patients were reviewed. Seven PET scans were recorded before the initial chemotherapy, and the remaining 41 scans were conducted during and after chemotherapy. Thymic FDG uptake was evaluated using standardized uptake value (SUV) analysis. The effect of chemotherapy on thymic FDG uptake was assessed by comparing SUV before, during, and after chemotherapy. The change in thymic FDG uptake with increasing time after the completion of chemotherapy was also assessed. Clinical laboratory data including number of white blood cells (WBCs), erythrocytes (RBCs), platelets, plasma glucose level and differential white blood count were analyzed for their association with thymic FDG uptake. Thymic FDG uptake in patients during chemotherapy was significantly lower than that in patients before chemotherapy (mean±SD 1.71±0.48 vs 2.27±0.32, respectively, P<0.01). Thymic FDG uptake in patients after chemotherapy was significantly higher than that in patients during chemotherapy (mean±SD 2.74±0.70 vs 1.71±0.48, respectively, P<0.01). A significant relationship between thymic FDG uptake and interval after completion of chemotherapy (r=0.74, P<0.0001) was observed. Significant relationships between blood counts (WBCs, RBCs, and platelets) and thymic FDG uptake were also observed. Comparison of the differential white blood count and thymic FDG uptake revealed a significant relationship only with lymphocyte count. Thymic FDG uptake in pediatric patients after completion of chemotherapy should not be mistaken as recurrent or metastatic thymic malignancy. Thymic FDG uptake appears to be associated with thymic function or hematopoietic function in bone marrow. Interpretation of FDG-PET must be made with this consideration in mind.

Kawabe J, Okamura T, Shakudo M, et al. Physiological FDG uptake in the palatine tonsils. Ann Nucl Med 2001; 15:297–300.PubMed

Cook GJ, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med 1996; 26:308–314.PubMed

Engel H, Steinert H, Buck A, et al. Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations. J Nucl Med 1996; 37:441–446.PubMed

Patel PM, Alibazoglu H, Ali A, et al. Normal thymic uptake of FDG on PET imaging. Clin Nucl Med 1996; 21:772–775.CrossRefPubMed

Brink I, Reinhardt MJ, Hoegerle S, et al. Increased metabolic activity in the thymus gland studied with¹⁸F-FDG PET: age dependency and frequency after chemotherapy. J Nucl Med. 2001; 42:591–595.

Weinblatt ME, Zanzi I, Belakhlef A, et al. False-positive FDG-PET imaging of the thymus of a child with Hodgkin’s disease. J Nucl Med 1997; 38:888–890.PubMed

Yoon SN, Park CH, Kim MK, et al. False-positive F-18 FDG gamma camera positron emission tomographic imaging resulting from inflammation of an anterior mediastinal mass in a patient with non-Hodgkin’s lymphoma. Clin Nucl Med 2001; 26:461–462.PubMed

Montravers F, McNamara D, Landman-Parker J, et al. [¹⁸F]FDG in childhood lymphoma: clinical utility and impact on management. Eur J Nucl Med Mol Imaging 2002; 29:1155–1165.CrossRefPubMed

Shin MS, Ho KJ. Diffuse thymic hyperplasia following chemotherapy for nodular sclerosing Hodgkin’s disease. An immunologic rebound phenomenon? Cancer 1983; 51:30–33.PubMed

10.

Choyke PL, Zeman RK, Gootenberg JE, et al. Thymic atrophy and regrowth in response to chemotherapy: CT evaluation. AJR 1987; 149:269–272.

11.

Kissin CM, Husband JE, Nicholas D, et al. Benign thymic enlargement in adults after chemotherapy: CT demonstration. Radiology 1987; 163:67–70.PubMed

12.

Bell BA, Esseltine DW, Azouz EM. Rebound thymic hyperplasia in a child with cancer. Med Pediatr Oncol 1984; 12:144–147.PubMed

13.

Hamacher K, Coenen HH, Stoeclin G. Efficient stereospecific synthesis of no-carrier-added 2-[¹⁸F]-fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986; 27:235–238.PubMed

14.

Inoue T, Oriuchi N, Kunio M, et al. Accuracy of standardized uptake value(SUV) measured by simultaneous emission and transmission scanning in PET oncology. Nucl Med Commun 1999; 20:849–857.PubMed

15.

Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-d-glucose: variations with body weight and a method for correction. Radiology 1993; 189:847–850.PubMed

16.

Langer KJ, Braun U, Kops ER, et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinoma. J Nucl Med 1993; 34:355–359.PubMed

17.

Mackall CL, Fleisher TA, Brown MR, et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994; 84:2221–2228.PubMed

18.

Mackall CL, Fleisher TA, Brown MR, et al. Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood 1997; 89:3700–3707.PubMed

19.

Mackall CL, Fleisher TA, Brown MR, et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995; 332:143–149.CrossRefPubMed

20.

Kubota R, Yamada S, Kubota K, et al. Intratumoral distribution of fluorine-18-dluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissue studied by microautoradiology. J Nucl Med 1992; 33:1972–1980.PubMed

21.

Abbas AK, Lichtman AH. Cellular and molecular immunology, 5th edn. Philadelphia: Saunders, 2003.

22.

Donahue DM, Leonard JC, Basmadjian GP, et al. Thymic gallium-67 localization in pediatric patients on chemotherapy: concise communication. J Nucl Med 1981; 22:1043–1048.PubMed

Titel: The clinical relevance of thymic fluorodeoxyglucose uptake in pediatric patients after chemotherapy
verfasst von: Tsuyoshi Kawano
Akiko Suzuki
Amane Ishida
Nobukazu Takahashi
Jin Lee
Yoshifumi Tayama
Takashi Oka
Shumpei Yokota
Tomio Inoue
Publikationsdatum: 01.06.2004
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 6/2004
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-004-1466-4

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The clinical relevance of thymic fluorodeoxyglucose uptake in pediatric patients after chemotherapy

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2004

Requirements for clinical PET: clarification of the situation in Sweden

High expression of peptide receptors as a novel target in gastrointestinal stromal tumours

Iodine-131 treatment and high-resolution CT: results in patients with lung metastases from differentiated thyroid carcinoma

Requirements for clinical PET: the situation in Switzerland

Sequence-specific DNA strand cleavage by 111In-labeled peptide nucleic acids

“Characterization of basal hepatic bile...”